Calyx and Invicro are now Perceptive
Independent review of trial event assessments by adjudication experts.
Proven expertise in delivering high-quality imaging data at a global scale.
With strengths in instrument engineering, signal processing, and pharmaceutical R&D, Perceptive Discovery consistently delivers successful imaging study designs and executions.
Effective RTSM, built on 30 years of experience, and connected to an ecosystem which includes eConsent and eCOA.
Highly established imaging centers for first-in-human and multicenter trials.
900+ agents radiolabeled and counting.
Supporting both malignant and non-malignant indications.
Experts in Alzheimer’s Disease, Parkinson’s Disease imaging and more.
Supporting over 85% of radiopharmaceutical companies.
Optimize preclinical and clinical trials in other areas and drug classifications.
Therapeutic and technical expertise in imaging modalities, protocol design, and acquisition.
Oncology imaging, RTSM, and clinical adjudication services.
Tackling unique rare disease trial supply, imaging and adjudication challenges.
We are here to serve science.
From discovery, through early to late-phase clinical development, to regulatory approval and post-market, you can count on Perceptive to be dependable, diligent, and driven in everything we do.
Perceptive Discovery bridges preclinical insights to early clinical success, ensuring rigorous scientific analysis and high-quality data to support innovation.
Providing the right-fit randomization & trial supply management solution for your trials, delivered by experts.
The right people, experience, and technology to drive clinical trial imaging success.
Generate early data to support your research initiatives with Perceptive Discovery’s best-in-class preclinical imaging services. Our seamless approach across early-phase R&D saves you time and ensures consistency, helping you to identify the most promising compounds and minimize risk.
Years of experience
Studies supported
Preclinical labs
Trusted partner offering radiochemistry, custom experimental design, execution, and results interpretation.
Adaptable approach to specialized imaging biomarker studies.
Multiple imaging facilities and strategic collaborations ensure agile study management and expanded capabilities.
Focus on collaboration ensures consistent growth, fostering long-term partnerships with sponsors.
Bespoke image analytics, pipelines, and cutting-edge tools deliver precise, tailored insights for sponsors.
Perceptive Discovery has vast preclinical experience supporting Neuroscience drug development. Our functional and molecular imaging solutions are well-suited for non-invasive longitudinal studies to provide multiple readouts, such as:
We use state-of-the-art imaging techniques to characterize the behavior of novel therapies and identify imaging biomarkers across diverse tumor model types (e.g. subcutaneous, orthotopic, metastatic).
Our core capabilities include:
Perceptive partners with sponsors to advance radiopharmaceutical therapy from proof-of-concept through late-phase trials. Our preclinical expertise in primary in vivo pharmacology services, radiochemistry, biodistribution, and dosimetry services supports optimized therapy development and accelerates progress toward first-in-human studies.
Our core capabilities include:
Perceptive Discovery offers an array of preclinical services that deliver high-fidelity data and actionable insights to support informed decision-making.
From the intricacies of molecular processes to the complexity of whole-body systems, we are committed to harnessing the power of advanced technologies to develop imaging biomarkers, ensuring every study is equipped with the tools necessary.
We utilize a comprehensive range of animal models to ensure translational relevance, from small rodents to non-human primates (NHPs). These models are meticulously chosen, developed, and managed to provide relevant and translatable data across therapeutic areas.
Radiolabeled compounds enable non-invasive evaluation of drug distribution, metabolism, and pharmacokinetics through PET and SPECT. Perceptive’s expertise in optimizing and synthesizing radiolabeled compounds ensures preclinical imaging studies are conducted with scientific rigor, accuracy, and safety, driving more efficient drug development.
Perceptive’s medical image analysis team specializes in developing advanced algorithms and pipelines to tackle complex image science challenges, extracting precise quantitative data for studies ranging from discovery research to late-phase clinical trials.
By combining the latest advancements in image science with engineering expertise, we innovate and refine new algorithms and automated and semi-automated image analysis processes to ensure efficient, reliable analysis.
We support a range of preclinical image analysis tasks, tailoring our approach based on the species, imaging modalities, and therapeutic focus. Using our in-house software, including VivoQuant and iPACS, we apply existing tools or develop new ones to meet the specific needs of each study while offering sponsors convenient access to image data and results.
VivoQuant is a powerful, vendor-neutral imaging software designed to deliver seamless image post-processing and analysis across multiple modalities and species. Engineered through collaboration with scientists, for scientists, VivoQuant empowers researchers by combining fundamental viewing functionality with powerful tools for fine-tuning images and isolating and analyzing regions of interest for quantitative analysis tailored to preclinical workflows.
With Perceptive’s translational imaging expertise, sponsors benefit from coordinated imaging protocol development across preclinical and first-in-human clinical studies.
Our streamlined approach saves time, reduces complexity, and supports regulatory success by delivering high-quality data and insights across translational research. Discover how our in-house imaging clinics in New Haven and London can advance your program.
Let’s discuss your next study.
Highly established clinical and imaging centers supporting first-in-human and multicenter studies.
Proven expertise in delivering high-quality clinical trial imaging data at a global scale.
